Hypoxia-driven selection of the metastatic phenotype
暂无分享,去创建一个
[1] Michael V. Doyle,et al. Regulation of Integrin Function by the Urokinase Receptor , 1996, Science.
[2] R. Gillies,et al. Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.
[3] R. Khokha,et al. Steps in tumor metastasis: new concepts from intravital videomicroscopy , 1995, Cancer and Metastasis Reviews.
[4] G. Semenza,et al. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. , 1997, Cancer research.
[5] R. Hill,et al. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[6] M. Toi,et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer , 1996, Cancer.
[7] J. Herman,et al. Methylation Patterns of the E-cadherin 5′ CpG Island Are Unstable and Reflect the Dynamic, Heterogeneous Loss of E-cadherin Expression during Metastatic Progression* , 2000, The Journal of Biological Chemistry.
[8] M. Goldberg,et al. Inhibition of Hypoxia-inducible Factor 1 Activation by Carbon Monoxide and Nitric Oxide , 1999, The Journal of Biological Chemistry.
[9] L. Trusolino,et al. Scatter-factor and semaphorin receptors: cell signalling for invasive growth , 2002, Nature Reviews Cancer.
[10] Ricky T. Tong,et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.
[11] P. Comoglio,et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.
[12] G. Semenza,et al. Carbon Monoxide and Nitric Oxide Suppress the Hypoxic Induction of Vascular Endothelial Growth Factor Gene via the 5′ Enhancer* , 1998, The Journal of Biological Chemistry.
[13] R. Khokha,et al. Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. , 1995, Cancer research.
[14] R. Khokha,et al. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. , 1994, Cancer research.
[15] F. Eschwège,et al. Intratumoral oxygen tension in metastatic melanoma , 1997, Melanoma research.
[16] Rakesh K Jain,et al. Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics , 2002, Science.
[17] L. Tacchini,et al. Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. , 2001, Carcinogenesis.
[18] N. Mackman,et al. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. , 1996, The Journal of biological chemistry.
[19] Adrian L. Harris,et al. Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.
[20] R. Hill,et al. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. , 2001, Cancer research.
[21] J. R. Kim,et al. Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] S. Leung,et al. Vascular endothelial growth factor is up‐regulated in the early pre‐malignant stage of colorectal tumour progression , 1999, International journal of cancer.
[23] A. Bosserhoff,et al. Loss of E-cadherin leads to upregulation of NFκB activity in malignant melanoma , 2004, Oncogene.
[24] C. Graham,et al. Nitric oxide signalling and cellular adaptations to changes in oxygenation. , 2005, Toxicology.
[25] S. Macdonald-Goodfellow,et al. Hypoxia‐mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression , 1999, International journal of cancer.
[26] J. Caro,et al. Hypoxia regulatory elements of the human vascular endothelial growth factor gene. , 1994, Cellular & molecular biology research.
[27] L. Liotta,et al. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. , 1974, Cancer research.
[28] M. Shin,et al. Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[29] W. Birchmeier,et al. Role of morphogenetic factors in metastasis of mammary carcinoma cells , 1998, Oncogene.
[30] A. Bosserhoff,et al. Expression of Dickkopf genes is strongly reduced in malignant melanoma , 2006, Oncogene.
[31] R. Jain,et al. Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors. , 1995, Microvascular research.
[32] G. Semenza,et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. , 2003, Cancer research.
[33] R. Hill,et al. Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion , 2004, Clinical & Experimental Metastasis.
[34] G. Christofori,et al. Hepatocyte growth factor induces cell scattering through MAPK/Egr‐1‐mediated upregulation of Snail , 2006, The EMBO journal.
[35] T. Ohtsuka,et al. Tumor–stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c‐Met pathway , 2006, International journal of cancer.
[36] A. Fyles,et al. Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancer. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[37] T. E. Fitzpatrick,et al. Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. , 1998, Blood.
[38] M. Tsao,et al. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. , 1992, Oncogene.
[39] A. Harris,et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[40] N. Mackman,et al. Requirement of Receptor-bound Urokinase-type Plasminogen Activator for Integrin αvβ5-directed Cell Migration* , 1996, The Journal of Biological Chemistry.
[41] L. Chung,et al. Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells , 2006, Clinical & Experimental Metastasis.
[42] Hadassa Degani,et al. High-resolution magnetic resonance imaging of disparities in the transcapillary transfer rates in orthotopically inoculated invasive breast tumors. , 2004, Cancer research.
[43] J. D. Chapman,et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age , 2000, Cancer.
[44] D. Chung,et al. Hypoxia-Inducible Factor-1-Independent Regulation of Vascular Endothelial Growth Factor by Hypoxia in Colon Cancer , 2004, Cancer Research.
[45] H. Kuwano,et al. Autocrine Motility Factor Signaling Enhances Pancreatic Cancer Metastasis , 2004, Clinical Cancer Research.
[46] R. Hill,et al. Effects of reoxygenation on cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential. , 1990, Journal of the National Cancer Institute.
[47] K Satyamoorthy,et al. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. , 2001, Cancer research.
[48] P. Russell,et al. Urokinase‐type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer‐specific survival and potential therapeutic targets , 2000, International journal of cancer.
[49] S. Eccles,et al. Phosphoinositide 3-Kinase Signalling Pathways in Tumor Progression, Invasion and Angiogenesis , 2004, Tumori.
[50] K. Tsukinoki,et al. Hepatocyte growth factor and c-Met immunoreactivity are associated with metastasis in high grade salivary gland carcinoma. , 2004, Oncology reports.
[51] A. Pasquini,et al. Increased expression of Met protein is associated with up‐regulation of hypoxia inducible factor‐1 (HIF‐1) in tumour cells in papillary carcinoma of the thyroid , 2004, The Journal of pathology.
[52] M. Simon. Mitochondrial reactive oxygen species are required for hypoxic HIF alpha stabilization. , 2006, Advances in experimental medicine and biology.
[53] H. Kobayashi,et al. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. , 1994, Cancer research.
[54] G. Semenza,et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.
[55] Mariann Bienz,et al. β-Catenin: A Pivot between Cell Adhesion and Wnt Signalling , 2005, Current Biology.
[56] A. Mercurio,et al. The epithelial-mesenchymal tansition (EMT) and colorectal cancer progression , 2005, Cancer biology & therapy.
[57] R. Jain,et al. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. , 2000, Cancer research.
[58] Helen H. W. Chen,et al. Hypoxia-inducible factor-1α correlates with MET and metastasis in node-negative breast cancer , 2007, Breast Cancer Research and Treatment.
[59] D. Mottet,et al. HIF‐1 and AP‐1 Cooperate to Increase Gene Expression in Hypoxia: Role of MAP Kinases , 2001, IUBMB life.
[60] H. Beug,et al. Epithelial-Mesenchymal Transition: NF-κB Takes Center Stage , 2004 .
[61] I. Macdonald,et al. Clinical targets for anti-metastasis therapy. , 2000, Advances in cancer research.
[62] Rakesh K. Jain,et al. Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.
[63] L. Tacchini,et al. Hepatocyte growth factor signaling regulates transactivation of genes belonging to the plasminogen activation system via hypoxia inducible factor-1. , 2003, Experimental cell research.
[64] M. Oya,et al. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. , 2007, Carcinogenesis.
[65] M. Simon. Mitochondrial Reactive Oxygen Species are Required for Hypoxic HIFα Stabilization , 2006 .
[66] C. Wykoff,et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.
[67] R. Jain. The next frontier of molecular medicine: Delivery of therapeutics , 1998, Nature Medicine.
[68] P. Schumacker,et al. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia , 2006, Experimental physiology.
[69] Y. Nakamura,et al. Cloning, expression and mapping of a novel human zinc-finger gene TCF17 homologous to rodent Kid1. , 1997, Cytogenetics and cell genetics.
[70] K. Karube,et al. Prognostic significance of hepatocyte growth factor and c‐MET expression in patients with diffuse large B‐cell lymphoma , 2004, British journal of haematology.
[71] E. Rofstad,et al. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. , 2002, Cancer research.
[72] M. Pierotti,et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. , 1992, Oncogene.
[73] D. He,et al. Hypoxia-inducible factor-1alpha induces the epithelial-mesenchymal transition of human prostatecancer cells. , 2006, Chinese medical journal.
[74] Eamonn R. Maher,et al. Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein* , 2000, The Journal of Biological Chemistry.
[75] H. Beug,et al. Epithelial-mesenchymal transition: NF-kappaB takes center stage. , 2004, Cell cycle.
[76] E. Rofstad,et al. Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. , 2002, Cancer research.
[77] M Ancukiewicz,et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. , 2000, Cancer research.
[78] M. Nieto,et al. The Snail genes as inducers of cell movement and survival: implications in development and cancer , 2005, Development.
[79] L. Ellis,et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. , 1995, Cancer research.
[80] N. Weidner,et al. Tumor angiogenesis: review of current applications in tumor prognostication. , 1993, Seminars in diagnostic pathology.
[81] M. Dellian,et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factoryvascular permeability factor antibody (angiogenesisyvascular obstruction) , 1996 .
[82] C. Graham,et al. Nitric oxide‐mediated regulation of hypoxia‐induced B16F10 melanoma metastasis , 2004, International journal of cancer.
[83] S. Nathanson,et al. Insights into the mechanisms of lymph node metastasis , 2003, Cancer.
[84] R. Klausner,et al. The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells , 1999, Molecular and Cellular Biology.
[85] W. Kaelin,et al. The von Hippel-Lindau tumor suppressor gene. , 2001, Experimental cell research.
[86] D A Hilton,et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.
[87] F. Jänicke,et al. Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix , 1999, The Journal of pathology.
[88] A. Hanlon,et al. Hypoxic regions exist in human prostate carcinoma. , 1999, Urology.
[89] O. Melnyk,et al. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. , 1996, Cancer research.
[90] S. Dower,et al. Response of tumour cells to hypoxia: role of p53 and NFkB. , 1998, Molecular pathology : MP.
[91] M. Goldberg,et al. Post-transcriptional Regulation of Vascular Endothelial Growth Factor by Hypoxia (*) , 1996, The Journal of Biological Chemistry.
[92] F. Spagnoli,et al. Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes , 1997, The EMBO journal.
[93] Vyacheslav Kalchenko,et al. Real-time imaging of lymphogenic metastasis in orthotopic human breast cancer. , 2006, Cancer research.
[94] J. Alexander,et al. Vascular Permeability Factor/Vascular Endothelial Cell Growth Factor-mediated Permeability Occurs through Disorganization of Endothelial Junctional Proteins* , 1998, The Journal of Biological Chemistry.
[95] K. Webster,et al. Molecular Regulation of the Endothelin-1 Gene by Hypoxia , 2001, The Journal of Biological Chemistry.
[96] T. Danielsen,et al. Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis , 1999, British Journal of Cancer.
[97] T. Nikaido,et al. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. , 2003, The American journal of pathology.
[98] M. Norris,et al. Hypoxia-induced Protein Binding to O2-responsive Sequences on the Tyrosine Hydroxylase Gene (*) , 1995, The Journal of Biological Chemistry.
[99] J. Pouysségur,et al. p42/p44 Mitogen-activated Protein Kinases Phosphorylate Hypoxia-inducible Factor 1α (HIF-1α) and Enhance the Transcriptional Activity of HIF-1* , 1999, The Journal of Biological Chemistry.
[100] H. Pehamberger,et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. , 2004, The Journal of clinical investigation.
[101] Richard D Klausner,et al. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.
[102] B. Nordlinger,et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[103] S. Oh,et al. uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line , 2006, Cell Research.
[104] A. Maity,et al. Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia. , 2000, Experimental cell research.
[105] P. Vaupel,et al. Hypoxic cervical cancers with low apoptotic index are highly aggressive. , 1999, Cancer research.
[106] E. Rimm,et al. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma , 1999, Cancer.
[107] F. Galimi,et al. Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. , 1994, The Journal of biological chemistry.
[108] K. Nakashiro,et al. Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. , 2006, Oral oncology.
[109] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. , 1999, Current topics in microbiology and immunology.
[110] R. Reed,et al. Inhibition of carcinoma cell‐derived VEGF reduces inflammatory characteristics in xenograft carcinoma , 2006, International journal of cancer.
[111] I. Macdonald,et al. Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth , 1994, Clinical & Experimental Metastasis.
[112] D. Peet,et al. Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch , 2002, Science.
[113] Tae-Hee Lee,et al. Vascular Endothelial Growth Factor Modulates the Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell Permeability* , 2003, The Journal of Biological Chemistry.
[114] P. Gullino,et al. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. , 1975, Cancer research.
[115] M. Oya,et al. Renal cancer cells lacking hypoxia inducible factor (HIF)-1α expression maintain vascular endothelial growth factor expression through HIF-2α , 2006 .
[116] R. Hill. Tumor progression: Potential role of unstable genomic changes , 1990, Cancer and Metastasis Reviews.
[117] C. Graham,et al. Oxygen-mediated Regulation of Tumor Cell Invasiveness , 2002, The Journal of Biological Chemistry.
[118] D. Goeddel,et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.
[119] E. Rofstad,et al. The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products. , 2005, Cancer research.
[120] M. Dewhirst,et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. , 1996, Cancer research.
[121] Y. Yuan,et al. Responding to Hypoxia: Lessons From a Model Cell Line , 2002, Science's STKE.
[122] E. Manseau,et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. , 1996, Cancer research.
[123] M. Corada,et al. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. , 1998, Journal of cell science.
[124] E. Keshet,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.
[125] M. Goldberg,et al. Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia (*) , 1995, The Journal of Biological Chemistry.
[126] Francisco Portillo,et al. The transcription factor Snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression , 2000, Nature Cell Biology.
[127] M. Dewhirst,et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.
[128] M. Fiscella,et al. The mutationally activated Met receptor mediates motility and metastasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[129] P Vaupel,et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.
[130] G. Semenza,et al. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. , 2000, Cancer.
[131] H. Lyng,et al. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. , 1998, British Journal of Cancer.
[132] G. Semenza. Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.
[133] Kiichi Hirota,et al. Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. , 2005, Biochemical and biophysical research communications.
[134] J. Brown,et al. Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.
[135] Andreas Sommer,et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression , 2004 .
[136] G. Semenza,et al. Expression of hypoxia‐inducible factor 1α in brain tumors , 2000 .
[137] M. Makuuchi,et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. , 2000, Blood.
[138] A. Bosserhoff,et al. Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma , 2006, Oncogene.
[139] G. Semenza,et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[140] Jessica Lo,et al. HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .
[141] H. Dvorak,et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.
[142] H. Ryan,et al. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. , 1998, The EMBO journal.
[143] R. Raval,et al. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. , 2006, Cancer research.
[144] P. Comoglio,et al. Hepatocyte growth factor is a pleiotropic factor protecting epithelial cells from apoptosis. , 1996, Cell death and differentiation.
[145] L. Trusolino,et al. HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[146] D. Cheresh,et al. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis , 2004, The Journal of cell biology.
[147] M. Duffy,et al. Urokinase plasminogen activator: A prognostic marker in multiple types of cancer , 1999, Journal of surgical oncology.
[148] P. Carmeliet,et al. Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis (vol 394, pg 485, 1998) , 1998 .
[149] O. Arrieta,et al. Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas. , 2004, Cancer letters.
[150] E. Rimm,et al. Expression of c‐met is a strong independent prognostic factor in breast carcinoma , 1998, Cancer.
[151] F. Blasi,et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.
[152] D. Waltz,et al. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. , 1994, The Journal of biological chemistry.
[153] G. Semenza,et al. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. , 2006, Cancer research.
[154] J. Folkman,et al. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.
[155] W. Risau,et al. Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. , 1997, The Biochemical journal.
[156] Helen H. W. Chen,et al. Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. , 2007, Breast cancer research and treatment.
[157] L. H. Gray,et al. The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.
[158] H. Höfler,et al. Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.
[159] S. Bapat,et al. Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. , 2005, Gynecologic oncology.
[160] G. V. Vande Woude,et al. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[161] M. Toi,et al. Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer , 1994, Japanese journal of cancer research : Gann.